There were 388 press releases posted in the last 24 hours and 155,251 in the last 365 days.

DEADLINE ALERT: Brower Piven Reminds Investors Of The March 13, 2017 Deadline In Class Action Lawsuit And Encourages Investors With Losses In Excess of $100,000 From Investment In Novo Nordisk A/S (NVO) To Contact The Firm

STEVENSON, Md., March 05, 2017 (GLOBE NEWSWIRE) -- The securities litigation law firm of Brower Piven, A Professional Corporation, announces that a class action lawsuit has been commenced in the United States District Court for the District of New Jersey on behalf of purchasers of Novo Nordisk A/S (NYSE:NVO) (“Novo Nordisk” or the “Company”) American Depositary Receipts (“ADRs”) expanding the class period to February 5, 2015 and October 27, 2016, inclusive (the “Class Period”).  Investors who wish to become proactively involved in the litigation have until March 13, 2017 to seek appointment as lead plaintiff.

If you wish to choose counsel to represent you and the Class, you must apply to be appointed lead plaintiff and be selected by the Court.  The lead plaintiff will direct the litigation and participate in important decisions including whether to accept a settlement for the Class in the action.  The lead plaintiff will be selected from among applicants claiming the largest loss from investment in Novo Nordisk ADRs during the Class Period.  Members of the Class will be represented by the lead plaintiff and counsel chosen by the lead plaintiff.  No class has yet been certified in the above action.

The complaint accuses the defendants of violations of the Securities Exchange Act of 1934 by virtue of the defendants’ failure to disclose during the Class Period that Company’s reported earnings and forecasts were inflated through the collusive price fixing of the Company’s insulin drugs.

According to the complaint, following an August 5, 2016 announcement of disappointing earnings for the second quarter of 2016, an August 9, 2016 analyst report that disclosed that major net pricing upgrades in the U.S. will be the exceptions as opposed to the norm, and there will be no quick rebound from the Company’s stagnated growth, and an October 28, 2016 announcement that the Company was cutting its long-term profit growth by 50% and that it received a Civil Investigative Demand from the U.S. Attorney’s Office for the Southern District of New York seeking information relating to contracts and business relationships concerning its insulin products, the value of Novo Nordisk American Depositary shares declined significantly.

If you have suffered a loss in excess of $100,000 from investment in Novo Nordisk ADRs purchased on or after February 5, 2015 and held through the revelation of negative information during and/or at the end of the Class Period and would like to learn more about this lawsuit and your ability to participate as a lead plaintiff, without cost or obligation to you, please visit our website at  You may also request more information by contacting Brower Piven either by email at or by telephone at (410) 415-6616.  Brower Piven also encourages anyone with information regarding the Company’s conduct during the period in question to contact the firm, including whistleblowers, former employees, shareholders and others.

Attorneys at Brower Piven have extensive experience in litigating securities and other class action cases and have been advocating for the rights of shareholders since the 1980s.  If you choose to retain counsel, you may retain Brower Piven without financial obligation or cost to you, or you may retain other counsel of your choice.  You need take no action at this time to be a member of the class.

CONTACT:  Charles J. Piven
Brower Piven, A Professional Corporation
1925 Old Valley Road
Stevenson, Maryland 21153
Telephone: 410-415-6616

/EIN News/ --

Distribution channels: Consumer Goods, Law

EIN Presswire does not exercise editorial control over third-party content provided, uploaded, published, or distributed by users of EIN Presswire. We are a distributor, not a publisher, of 3rd party content. Such content may contain the views, opinions, statements, offers, and other material of the respective users, suppliers, participants, or authors.